"Company is weighing strategic options which incl
Post# of 30028
Posted On: 08/14/2014 12:07:07 PM
Re: SouthBreeze #3772
"Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro)
I just see with a Spin-Out, both partners for LymPro and for CLIA would want both LymPro & NuroPro. No way would they take LymPro thinking it will be a "modest" money maker and another diagnostic that isn't "going anywhere."
I think there are things going on that are going to push NuroPro forward faster than anyone is speaking about. And it's directly tied to ELTOP.
Not to mention ELTOP entering the next phase would be yet another spotlight..
"The potential market opportunity for a drug that could treat LID exceeds $750M annually in the United States alone."
I just see with a Spin-Out, both partners for LymPro and for CLIA would want both LymPro & NuroPro. No way would they take LymPro thinking it will be a "modest" money maker and another diagnostic that isn't "going anywhere."
I think there are things going on that are going to push NuroPro forward faster than anyone is speaking about. And it's directly tied to ELTOP.
Not to mention ELTOP entering the next phase would be yet another spotlight..
"The potential market opportunity for a drug that could treat LID exceeds $750M annually in the United States alone."
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼